Menu
This biomarker test can detect α-synuclein with 87% sensitivity, 97% specificity, and 93.9% accuracy.
Identifying Lewy body pathology at the MCI stage allows for a more personalized approach to disease management.
Ongoing studies indicate the need for early diagnosis and better definition of AD sub-types.
“Our results support a role for α-synuclein even in MCI, the early phase of AD, in addition to being a potential contributor in MCI and AD diagnosis or monitoring of disease progression.” Reference
“RT-QuIC (a research version of SAA) “identified patients with MCI-LB against cognitively unimpaired controls with 95% sensitivity, 97% specificity, and 96% accuracy and showed 98% specificity in neuropathologic controls.” Reference
Download the SAAmplify-ɑSYN Test Specification Sheet for details.
A pioneer in the science of detecting misfolded proteins, Amprion advances the diagnosis of brain disorders. Our SAAmplify™-ɑSYN Test aids physicians in diagnosing Parkinson’s, Lewy body dementia, and Alzheimer’s with Lewy body variant. We plan to launch more biomarker tests in the future.
